Â鶹ŮÓÅ

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • Â鶹ŮÓÅ Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

TRENDING TOPICS:

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Aug 18 2023

Full Issue

Weight-Loss Drugs In The US Cost Many Times The Price Paid Elsewhere

The Hill covers a Â鶹ŮÓÅ analysis that found the price hikes for drugs like Ozempic and Wegovy in the U.S. are sizable compared to other wealthy nations — the list price is 10 times less in some places. Among other news items: a look at Big Pharma's high-price playbook, and news on HIV and its treatment.

The prices charged for drugs like Ozempic, Wegovy and Mounjaro are significantly higher in the U.S. when compared with other wealthy nations, with the list price being 10 times lower in some countries, according to a new analysis from Â鶹ŮÓÅ. As Â鶹ŮÓÅ’s analysis found, a one-month supply of Ozempic — which is indicated for diabetes but is sometimes prescribed for weight loss off-label — has a list price of $936 in the U.S. Among the nine other countries that Â鶹ŮÓÅ looked at, none paid more than $200 for a month’s supply of the same drug. (Choi, 8/17)

Â鶹ŮÓÅ Health News: A Peek At Big Pharma’s Playbook That Leaves Many Americans Unable To Afford Their Drugs 

America’s pharmaceutical giants are suing this summer to block the federal government’s first effort at drug price regulation. Last year’s Inflation Reduction Act included what on its face seems a modest proposal: The federal government would for the first time be empowered to negotiate prices Medicare pays for drugs — but only for 10 very expensive medicines beginning in 2026 (an additional 15 in 2027 and 2028, with more added in later years). Another provision would require manufacturers to pay rebates to Medicare for drug prices that increased faster than inflation. (Rosenthal, 8/18)

On HIV/AIDS —

Iowa leads the nation in suppressing HIV in patients who are diagnosed with the disease, according to the most recent 2021 analysis by the Centers for Disease Control. Medication can delay HIV-positive people from getting AIDS, as well as prevent sexual transmission of the disease. (Ta, 8/17)

The fight against the HIV epidemic has seen a number of good milestones lately — the World Health Organization reaffirmed July 22 that those who consistently take antiretroviral treatment and maintain undetectable viral loads don't transmit the virus during sex. But those who've acquired HIV infection tell the Bay Area Reporter that they're still fighting for their lives. "As HIV gets older, so are we getting older," Hulda Brown, a 79-year-old straight ally, said in a recent interview. "We need different housing, safer housing, and chairlifts. You may need to walk with a cane. As you get older, we've had to adjust. We need a place to go to find services to explain to us the changes happening in our body, and how we can adapt." (Ferrannini, 8/16)

Gilead Sciences reached a $246.8 million settlement with direct purchasers of its HIV medications over allegations it made a deal with Teva Pharmaceuticals to delay generic versions of the drugs, Law360 reports. (Bucher, 8/17)

A feud has erupted between ViiV Healthcare and Doctors Without Borders over a deal to allow the relief organization to purchase an injectable HIV prevention drug, the latest fracas involving the company and efforts to distribute its medication to mostly poor locations around the world. (Silverman, 8/17)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 Â鶹ŮÓÅ